|
|
Article: Tissue processing company revises second quarter results.
- Article from:
- Biotech Week
- Article date:
- October 23, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 OCT 23 - (NewsRx.com & NewsRx.net) -- CryoLife, Inc., (CRY), a life-science company involved in the development and commercialization of cryopreserved and manufactured implantable tissues and surgical adhesives, reported that it filed its 10-Q for the quarter ended June 30, 2002.
The document is certified by the company's CEO and CFO.
CryoLife revised its previously announced 2002 second quarter results due to the U.S. Food and Drug Administration order it received on August 13, 2002, which ordered non-valved cardiac, vascular, and orthopedic tissue processed since October 3, 2001, by CryoLife to be retained "until it is recalled, destroyed, the ...